Home / Business and Economy / Hengrui Pharma: Pioneering New Cancer Therapies
Hengrui Pharma: Pioneering New Cancer Therapies
18 Sep
Summary
- Focuses on advanced oncology research including kinase inhibitors and ADCs.
- Develops drugs for autoimmune, metabolic, cardiovascular, and other diseases.
- Operates and sells products in both domestic Chinese and international markets.
Jiangsu Hengrui Pharmaceuticals Co Ltd, a prominent China-based entity, is dedicated to the research, development, production, and sale of pharmaceutical products. The company's primary focus is on the complex field of oncology, exploring diverse therapeutic avenues.
Their research encompasses areas such as kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, and hormone receptor regulation. The company also investigates DNA repair mechanisms and epigenetics, alongside supportive care for cancer patients.
Hengrui's product range includes vital anti-tumor medications, analgesic and anesthetic agents, and contrast agents. These treatments are applied across numerous medical fields, addressing autoimmune, metabolic, cardiovascular, and infectious diseases, among others.
The company actively engages in both its domestic market and international territories. This broad operational scope allows Hengrui to distribute its pharmaceutical innovations globally.
